3:25-cv-17384
Amneal Pharma LLC v. Sandoz Inc
I. Executive Summary and Procedural Information
- Parties & Counsel:
- Plaintiff: Amneal Pharmaceuticals LLC and Impax Laboratories, LLC (Delaware)
- Defendant: Sandoz Inc. (Delaware)
- Plaintiff's Counsel: Stone Conroy LLC
- Case Identification: 3:25-cv-17384, D.N.J., 04/15/2026
- Venue Allegations: Venue is based on Defendant Sandoz Inc.'s principal place of business in New Jersey, its continuous business activities within the district, and its alleged consent to venue in prior related actions.
- Core Dispute: Plaintiff alleges that Defendant's Abbreviated New Drug Application (ANDA) to market a generic version of CREXONT® (carbidopa/levodopa) infringes six U.S. patents related to pharmaceutical formulations and dosing regimens for treating Parkinson's disease.
- Technical Context: The technology involves advanced drug delivery systems for levodopa, aiming to provide more stable plasma concentrations and reduce motor fluctuations in Parkinson's disease patients, a key challenge in long-term treatment.
- Key Procedural History: This is a patent infringement action under the Hatch-Waxman Act, triggered by Defendant's ANDA submission. The complaint notes that Defendant provided a Paragraph IV certification notice for only one of the six patents-in-suit (the '163 patent). For the remaining five patents, Plaintiffs allege infringement based on the ANDA submission itself and Defendant's notices for other patents in the same families, asserting this evidences a clear intent to seek approval before patent expiration. The complaint also references two related, prior actions involving the same drug product but different patents.
Case Timeline
| Date | Event |
|---|---|
| 2013-10-07 | Priority Date for '099 Patent Family ('099, '164) |
| 2020-12-22 | Priority Date for '163 Patent Family ('163, '139, '710, '616) |
| 2024-11-25 | Plaintiffs received Paragraph IV notice for other patents (related cv-00181 Action) |
| 2025-01-30 | Plaintiffs received second Paragraph IV notice for other patents (related cv-00181 Action) |
| 2025-05-15 | Plaintiffs received first Paragraph IV notice for other patents (related cv-11981 Action) |
| 2025-07-29 | U.S. Patent No. 12,370,163 Issues |
| 2025-08-07 | Plaintiffs received second Paragraph IV notice for other patents (related cv-11981 Action) |
| 2025-09-02 | U.S. Patent No. 12,403,099 Issues |
| 2025-09-30 | Plaintiffs received Paragraph IV notice letter for the '163 patent |
| 2025-10-21 | U.S. Patent No. 12,447,139 Issues |
| 2025-10-28 | U.S. Patent No. 12,453,710 Issues |
| 2025-11-04 | U.S. Patent No. 12,458,616 Issues |
| 2025-12-09 | U.S. Patent No. 12,491,164 Issues |
| 2026-04-15 | First Amended Complaint Filed |
II. Technology and Patent(s)-in-Suit Analysis
U.S. Patent No. 12,370,163 - "Levodopa Dosing Regimen"
Issued July 29, 2025 Compl. ¶20
The Invention Explained
- Problem Addressed: The patent describes the difficulty in maintaining stable plasma concentrations of levodopa (LD) due to its short half-life (about 1.5 hours with a decarboxylase inhibitor) and narrow absorption window in the upper gastrointestinal tract, leading to motor fluctuations and "wearing-off" effects in Parkinson's disease (PD) patients '163 Patent, col. 1:29-54
- The Patented Solution: The patent claims a specific method of treatment for "levodopa naïve" PD patients, involving a twice-a-day oral dosing regimen of a particular controlled-release LD formulation. This regimen is asserted to improve motor state, reduce motor symptoms like tremor and dyskinesia, and lower scores on the Unified Parkinson's Disease Rating Scale (MDS-UPDRS), thereby providing more consistent therapeutic benefit than standard immediate-release formulations '163 Patent, abstract '163 Patent, col. 3:15-24 Figure 1 of the patent illustrates the different plasma concentration profiles of the patented formulation (labeled IPX203) versus an immediate-release version, showing a slower, more sustained release for the invention '163 Patent, FIG. 1
- Technical Importance: A twice-daily oral regimen that provides consistent therapeutic benefit would represent a significant improvement in convenience and clinical stability for PD patients, especially those new to levodopa therapy '163 Patent, col. 2:32-38
Key Claims at a Glance
- The complaint asserts independent claims 1 and 23, and dependent claim 12 Compl. ¶50
- Independent Claim 1 requires:
- A method for treating a levodopa naïve patient with Parkinson's disease.
- Comprising orally administering a multiparticulate controlled release levodopa dosage form twice a day.
- Wherein the patient has not been previously treated with levodopa.
- Wherein the dosing provides a reduction of from about 10%-40% in the patient's tremor, dyskinesia, and/or mobility.
- Independent Claim 23 requires:
- A method for treating a levodopa naïve patient with Parkinson's disease.
- Comprising orally administering a multiparticulate controlled release levodopa dosage form twice a day.
- Wherein the patient has not been previously treated with levodopa.
- Wherein the dosing reduces the patient's Movement Disorders Society version of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) scores by at least 3 points.
- The complaint reserves the right to assert additional claims Compl. ¶50
U.S. Patent No. 12,403,099 - "Muco-Adhesive, Controlled Release Formulation of Levodopa and/or Esters of Levodopa and Uses Thereof"
Issued September 2, 2025 Compl. ¶21
The Invention Explained
- Problem Addressed: The patent addresses the challenge of creating an effective oral extended-release levodopa (LD) formulation due to LD's short half-life and its limited absorption to a narrow window in the upper gastrointestinal tract '099 Patent, col. 1:52-65
- The Patented Solution: The invention is a multi-particulate oral dosage form containing both immediate-release and controlled-release components. The controlled-release portion is designed as beads with a specific multi-layer structure: a levodopa core, a rate-controlling membrane, a muco-adhesive layer to prolong transit time in the gut, and an outer enteric coating to prevent premature release in the stomach '099 Patent, abstract '099 Patent, FIG. 1 This structure is intended to provide both a rapid onset of effect and a prolonged, steady plasma concentration '099 Patent, col. 2:30-48 '099 Patent, col. 23:7-16
- Technical Importance: This formulation aims to mitigate the "peak-to-trough" fluctuations in plasma LD levels that are associated with motor complications in Parkinson's patients, offering a more stable therapeutic effect from an oral dose '099 Patent, col. 2:19-24
Key Claims at a Glance
- The complaint asserts independent claims 1 and 18 Compl. ¶63
- Independent Claim 1 requires:
- A capsule comprising 95 mg to 390 mg ±10% of levodopa.
- Containing one or more immediate release components comprising levodopa and carbidopa.
- Containing a plurality of controlled release components (beads) that are free of carbidopa and have a four-layer structure: (a) a levodopa core, (b) a controlled release coating, (c) a muco-adhesive coating, and (d) an enteric coating.
- Independent Claim 18 requires:
- A capsule comprising about 140 mg to about 350 mg levodopa.
- Consisting essentially of one or more immediate release beads or granules (comprising levodopa and carbidopa) and a plurality of controlled release beads (with the four-layer structure of claim 1).
- The complaint reserves the right to assert additional claims Compl. ¶66
U.S. Patent No. 12,447,139 - "Levodopa Dosing Regimen"
Issued October 21, 2025 Compl. ¶22
The Invention Explained
This patent, from the same family as the '163 patent, claims a method for treating PD patients with a controlled-release levodopa formulation. The method is asserted to improve a patient's total post-dose "On" time and "Good On" time compared to immediate-release levodopa tablets, addressing the core problem of managing motor fluctuations '139 Patent, abstract
Key Claims at a Glance
- Asserted Claims: Claims 1 and 13 are asserted Compl. ¶81
- Accused Features: The administration of Sandoz's proposed generic product to treat Parkinson's disease is alleged to directly infringe the claimed method Compl. ¶¶81-82
U.S. Patent No. 12,453,710 - "Levodopa Dosing Regimen"
Issued October 28, 2025 Compl. ¶23
The Invention Explained
Also in the '163 patent family, this patent claims a method for treating PD patients. The invention addresses the need for improved motor control by claiming a dosing regimen with a controlled-release LD formulation that provides an improved total post-dose "On" time and "Good On" time compared to immediate-release tablets '710 Patent, abstract
Key Claims at a Glance
- Asserted Claims: Claims 1 and 13 are asserted Compl. ¶96
- Accused Features: The use of Sandoz's proposed generic product for treating Parkinson's disease is alleged to infringe the claimed regimen Compl. ¶¶96-97
U.S. Patent No. 12,458,616 - "Levodopa Dosing Regimen"
Issued November 4, 2025 Compl. ¶24
The Invention Explained
This patent, also in the '163 family, claims a method of treating PD patients by administering a controlled-release levodopa formulation. The method is asserted to improve total post-dose "Off" time, "On" time, and "Good On" time compared to immediate-release levodopa tablets, addressing the problem of motor fluctuations in patients '616 Patent, abstract
Key Claims at a Glance
- Asserted Claims: Claims 1, 10, and 19 are asserted Compl. ¶111
- Accused Features: The complaint alleges that the use of Sandoz's proposed generic product according to its label will infringe the claimed method Compl. ¶¶111-112
U.S. Patent No. 12,491,164 - "Muco-Adhesive, Controlled Release Formulation of Levodopa and/or Esters of Levodopa and Uses Thereof"
Issued December 9, 2025 Compl. ¶25
The Invention Explained
This patent, from the same family as the '099 patent, is directed to a multi-particulate oral formulation for levodopa. It addresses the problem of levodopa's difficult pharmacokinetics by claiming a formulation with specific immediate-release and controlled-release components, the latter of which have a muco-adhesive feature to enhance and prolong drug absorption '164 Patent, abstract
Key Claims at a Glance
- Asserted Claims: Claims 1 and 12 are asserted Compl. ¶124
- Accused Features: Sandoz's proposed generic carbidopa/levodopa product is alleged to be the claimed formulation (Compl. ¶¶124; Compl. ¶128).
III. The Accused Instrumentality
Product Identification
The "Sandoz ANDA Products" are the subject of ANDA No. 219989. They are described as generic carbidopa/levodopa extended-release capsules for oral use in dosages of 35 mg/140 mg, 52.5 mg/210 mg, 70 mg/280 mg, and 87.5 mg/350 mg Compl. ¶29
Functionality and Market Context
The complaint alleges that the Sandoz ANDA Products are generic versions of Plaintiffs' CREXONT® product Compl. ¶1 It further alleges that by filing the ANDA, Sandoz has represented to the FDA that its products have the same active ingredients, method of administration, dosage forms, strengths, and are bioequivalent to CREXONT® Compl. ¶37 Upon approval, these products are intended to be marketed, sold, and prescribed for the treatment of Parkinson's disease, directly competing with Plaintiffs' branded product Compl. ¶30 Compl. ¶51 A visual from the patent attached to the complaint as Exhibit 1, Figure 1, shows the intended pharmacokinetic profile of the CREXONT® product, which Plaintiffs allege the Sandoz product will replicate '163 Patent, FIG. 1
IV. Analysis of Infringement Allegations
The complaint does not provide a detailed claim chart or specific, limitation-by-limitation evidence of infringement. The infringement theory is characteristic of ANDA litigation: it alleges that the product Sandoz seeks to market, as described in its ANDA, will infringe the asserted patents, and that the filing of the ANDA itself is a statutory act of infringement under 35 U.S.C. § 271(e)(2). The allegations rely on the representation that the Sandoz product is a generic equivalent of CREXONT® and will be used in a manner described on its FDA-approved label, which is expected to be substantively the same as the CREXONT® label Compl. ¶37 The following tables summarize the core allegations based on this theory.
'163 Patent Infringement Allegations
The complaint does not provide sufficient detail for a limitation-by-limitation analysis. The infringement theory is that the proposed label for the Sandoz ANDA Products will instruct medical professionals and patients to administer the drug in a way that practices the patented method, such as treating levodopa naïve patients Compl. ¶51, thereby inducing infringement.
'099 Patent Infringement Allegations
| Claim Element (from Independent Claim 1) | Alleged Infringing Functionality | Complaint Citation | Patent Citation |
|---|---|---|---|
| A capsule comprising...one or more immediate release components comprising levodopa and carbidopa, and a plurality of controlled release components... | The Sandoz ANDA Products are alleged to be extended-release capsules containing carbidopa and levodopa and to be bioequivalent to CREXONT®, which contains these components. | ¶29; ¶37 | col. 40:55-63 |
| wherein the plurality of controlled release components comprise: (a) a core comprising levodopa... | The Sandoz ANDA Products are alleged to have the same active ingredient and dosage form as CREXONT®, implying the presence of the claimed levodopa core. | ¶29; ¶37 | col. 40:40-41 |
| (c) a muco-adhesive coating comprising a poly(butyl methacrylate-co-(2-dimethylaminoethyl) methacrylate-co-methylmethacrylate) 1:2:1 surrounding the controlled release coating; and (d) an enteric coating... | The complaint alleges the Sandoz product is a generic equivalent of CREXONT®, implying it contains the claimed multi-layer structure, which is visually depicted in the patent. A key feature of the patented invention is the muco-adhesive and enteric coatings designed to control release. | ¶37 | col. 40:42-54; FIG. 1 |
Identified Points of Contention
- Scope Questions: A primary question for the method claims (e.g., in the '163 patent) will be whether the term "levodopa naïve patient" has a specific scope that can be definitively met or avoided by the language in Sandoz's proposed product label. For the formulation claims (e.g., in the '099 patent), a dispute may arise over the definition of "muco-adhesive coating" and whether the material used in the Sandoz product meets the functional and compositional requirements of the claims.
- Technical Questions: A core technical question for the formulation patents will be one of composition: does the Sandoz product actually contain the specific multi-layer bead structure, including a distinct "controlled release coating" and a "muco-adhesive coating," as claimed? For the method patents, an evidentiary question will be whether administration of the Sandoz product will, in fact, result in the clinical outcomes required by the claims (e.g., a specific percentage reduction in tremor or a 3-point reduction in MDS-UPDRS score).
V. Key Claim Terms for Construction
"levodopa naïve patient" ('163 Patent, Claim 1)
- Context and Importance: This term is critical for the method-of-use patents ('163, '139, '710, '616), as it defines the target patient population. The infringement analysis for induced infringement will depend on whether Sandoz's product label encourages or instructs use in this specific population.
- Intrinsic Evidence for Interpretation:
- Evidence for a Broader Interpretation: The specification refers to "newly diagnosed PD patients that have not begun LD treatment or are LD naïve patients" '163 Patent, col. 3:15-18 This language may support an interpretation that includes any patient who has not previously taken levodopa, regardless of other treatments.
- Evidence for a Narrower Interpretation: Practitioners may focus on the context of a "starting" dose regimen for patients who are initiating LD therapy for the first time '163 Patent, col. 3:36-40 This could support a narrower interpretation limited to the specific clinical scenario of a patient's first-ever prescription for levodopa, as opposed to a patient who has taken other PD drugs but not yet levodopa.
"muco-adhesive coating" ('099 Patent, Claim 1)
- Context and Importance: This term is a key structural limitation of the claimed controlled-release formulation. Infringement of the product-by-process patents ('099, '164) will likely hinge on whether the Sandoz formulation contains a coating that meets the definition of "muco-adhesive."
- Intrinsic Evidence for Interpretation:
- Evidence for a Broader Interpretation: The specification lists numerous examples of muco-adhesive polymers, including carbomer, cellulosics, and chitosan, suggesting the term could be construed broadly to cover a class of materials with adhesive properties '099 Patent, col. 26:5-15
- Evidence for a Narrower Interpretation: The patent describes a specific functional purpose for the coating: forming a positive ionic charge to interact with the negative charge of the intestinal walls to slow transit time '099 Patent, col. 26:30-39 The patent also identifies a specific cationic copolymer, Eudragit® E100, as a preferred material '099 Patent, col. 26:20-24 This may support a narrower construction limited to polymers that function via this ionic mechanism or are structurally similar to the preferred examples.
VI. Other Allegations
Indirect Infringement
The complaint alleges induced infringement for all asserted patents. The theory is that Sandoz, by marketing its ANDA products with an FDA-approved label, will knowingly and intentionally encourage and instruct healthcare professionals and patients to use the product in a manner that directly infringes the asserted method and formulation claims (Compl. ¶50; Compl. ¶51; Compl. ¶52; Compl. ¶53; Compl. ¶54). Contributory infringement is also alleged, on the basis that the Sandoz products are especially made for an infringing use and are not a staple article suitable for substantial non-infringing use Compl. ¶55 Compl. ¶71
Willful Infringement
While not pleaded as a separate count, the complaint lays the groundwork for willfulness. It alleges Sandoz has knowledge of the patents-in-suit through their listing in the FDA Orange Book (Compl. ¶¶48; Compl. ¶64). For the '163 patent, knowledge is also based on the Paragraph IV notice letter Sandoz provided Compl. ¶48 For the other five patents, the complaint alleges Sandoz has knowledge despite failing to send notice letters, pointing to notices sent for other patents in the same families Compl. ¶43 Compl. ¶64 The complaint seeks a finding of an exceptional case under 35 U.S.C. § 285 Compl. ¶58 Compl. ¶74
VII. Analyst's Conclusion: Key Questions for the Case
- A central issue will be one of structural infringement: does the Sandoz generic formulation, as detailed in its confidential ANDA submission, contain the specific multi-layer, muco-adhesive, controlled-release bead structure that is the cornerstone of the asserted formulation patents ('099 and '164)?
- A key legal question will be one of induced infringement: for the method-of-use patents ('163, '139, '710, '616), is the language on Sandoz's proposed product label sufficient to prove Sandoz actively encourages infringement, particularly for specific patient populations like "levodopa naïve" patients, and to achieve the claimed clinical outcomes?
- A significant procedural and substantive question will be the effect of Sandoz's alleged failure to provide Paragraph IV notice for five of the six asserted patents. The court will need to determine if this impacts the establishment of an "actual and immediate controversy" for those patents or Plaintiffs' ability to pursue claims for infringement based on the ANDA submission alone.